Drugs / Decitabine-primed Tandem CAR19/20 engineered T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04697940 | Apr 2021 → May 2025 overdue | B-cell non-Hodgkin lymphoma | Han weidong | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine-primed Tandem CAR19/20 engineered T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04697940 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T Cells” NCT04697940 ↗ |
| Route | Other | “cell infusion” NCT04697940 ↗ |
| Target | CD19 | “Decitabine-primed Tandem Targeting CD19 and CD20 Chimeric Antigen Receptor T Cells” NCT04697940 ↗ |